| Bioactivity | Urtoxazumab (TMA-15) is a humanized monoclonal antibody against Shiga toxin (Stx) 2[1]. |
| In Vivo | Urtoxazumab (TMA-15) (0.25-2.5 mg/kg;注射。一次)以时间和剂量依赖的方式改善 B2F1 感染小鼠的致死率[1]。 Animal Model: |
| Name | Urtoxazumab |
| CAS | 502496-16-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42. |